AVROAVROBIO, Inc.

Nasdaq avrobio.com


$ 1.35 $ 0.12 (9.76 %)    

Monday, 13-May-2024 15:56:38 EDT
QQQ $ 442.84 $ 1.02 (0.23 %)
DIA $ 394.52 $ -0.72 (-0.18 %)
SPY $ 520.61 $ 0.07 (0.01 %)
TLT $ 90.36 $ 0.23 (0.26 %)
GLD $ 216.28 $ -2.45 (-1.12 %)
$ 1.35
$ 1.23
$ 1.33 x 100
$ 0.00 x 0
$ 1.22 - $ 1.35
$ 0.57 - $ 1.70
860,922
na
60.47M
$ 1.41
$ 2.00
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-14-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-23-2023 12-31-2022 10-K
7 11-08-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-10-2022 03-31-2022 10-Q
10 03-17-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-13-2021 03-31-2021 10-Q
14 03-18-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 03-16-2020 12-31-2019 10-K
19 11-07-2019 09-30-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 05-13-2019 03-31-2019 10-Q
22 03-25-2019 12-31-2018 10-K
23 11-13-2018 09-30-2018 10-Q
24 08-09-2018 06-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 mizuho-downgrades-avrobio-to-neutral-lowers-price-target-to-2

Mizuho analyst Uy Ear downgrades Avrobio (NASDAQ:AVRO) from Buy to Neutral and lowers the price target from $5 to $2.

 wells-fargo-maintains-overweight-on-avrobio-lowers-price-target-to-2

Wells Fargo analyst Yanan Zhu maintains Avrobio (NASDAQ:AVRO) with a Overweight and lowers the price target from $2.5 to $2.

 why-lucid-group-shares-are-trading-lower-by-11-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Gainers Healthcare Triangle, Inc. (NASDAQ: HCTI) shares climbed 171.2% to $8.84 as the company launched initiative to preven...

 wedbush-downgrades-avrobio-to-neutral-announces-2-price-target

Wedbush analyst David Nierengarten downgrades Avrobio (NASDAQ:AVRO) from Outperform to Neutral and announces $2 price target.

 why-avrobio-shares-are-rising-wednesday

AVROBIO Inc (NASDAQ: AVRO) shares are trading higher Wednesday after the company said it will explore strategic alternatives.

Core News & Articles
Market-Moving News for July 12th
07/12/2023 12:34:20

AULT: 167% - Ault Alliance shares are trading higher after the company said it anticipates $200 million in annual revenue for 2...

 avrobio-stock-jumps-on-sale-of-gene-therapy-program-to-novartis

Shares of clinical-stage gene therapy company AVROBIO, Inc. (NASDAQ: AVRO) are trading higher Monday due to its agreement to se...

 dow-tumbles-100-points-micron-technology-shares-plunge

U.S. stocks traded mixed toward the end of trading, with the Dow Jones dropping over 100 points on Monday. The Dow traded down...

 why-zim-integrated-shipping-services-shares-are-trading-lower-by-14-here-are-other-stocks-moving-in-mondays-mid-day-session

Gainers Greenhill & Co., Inc. (NYSE: GHL) shares jumped 116.4% to $14.67 after Mizuho announced it would acquire the com...

 avrobio-offloads-gene-therapy-program-for-rare-genetic-disorder-to-novartis

Avrobio Inc (NASDAQ: AVRO) agreed to sell its investigational hematopoietic stem cell (HSC) gene therapy program for cystinosis...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION